Learn more about our collaboration with the APA: osmind.org/blog/osmind-apa-c…

Some people have tried three antidepressants. Five. Seven. And still haven’t found meaningful relief. That’s treatment-resistant depression (TRD), and an estimated 4 million Americans are living with it. Today, for the first time, it has its own awareness day. We’re proud to join @COMPASSPathway and leading advocacy organizations in marking #TRDawarenessday. Across the Osmind community, we see what’s possible when people with TRD reach clinicians who specialize in interventional treatment. Earlier this year, we helped define “interventional psychiatry” in Nature Mental Health, because shared language is how a field grows and how more patients find their way to it. Awareness is the first step. Earlier recognition is the next. Our mission is to help clinicians bring evidence-based treatments to the patients who need them most. If you or someone you love is living with TRD, you are not alone. #TRDawarenessday #DepressionAwarenessMonth #MentalHealth #InterventionalPsychiatry

"Anything that isn't directly related to that is something that we can potentially partner with Osmind with." - Michael Dinh, MD Revenue cycle management, charting, claims are all integrated. The alternative was two psychiatrists spending their week fighting for billing and haggling with insurance instead of being present with patients. Amast Health never had to build a back office because Osmind handles it all. Now Amast can focus on deliverying breakthrough treatments safely and profitably.

For two years, Sahab Yaqubi, M.D. ran his EHR in one system and his billing in another, connected by a clearinghouse and a shared folder. "The problem was that there were several systems. Here it's all one." PathWave Psychiatry now runs more than 220 encounters a month with Dr. Yaqubi as its only prescribing clinician, offering Spravato, TMS, and medication management to patients with treatment-resistant depression and anxiety. On Osmind 360, the practice collects from payers in about 26 days, ahead of the 35-day industry norm. For the first time, he can see his own revenue cycle numbers. “If you want to do simple medication management, without depending on Spravato prior authorizations, maybe other options can be helpful. But for an interventional psychiatry practice like ours, having the EHR, billing, and authorization workflows integrated in one platform has been a significant improvement” osmind.org/blog/pathwave-psy…

That's a wrap on back-to-back conferences: Behavioral Health Tech in Nashville and ASKP³ Mastering the Essentials in Denver. Thank you to everyone who stopped by our booth and to the speakers who sharpened our thinking. At BHT, our CEO Lucia Huang joined the psychedelics panel, which quickly converged on one theme: psychedelics in real-world practice will bring a level of complexity clinical trials haven't yet contemplated. Takeaways from both events: Matching patients to treatments. If multiple psychedelic therapies reach FDA approval, how will clinicians know which is right for each patient, and when? Nate Mohatt of ARPA-H made a compelling case for precision psychiatry and objective biomarkers to tailor treatment. Practice guidelines can't come soon enough. Sarah Norman shared the work BrainFutures is doing to establish them, while earning more laughs than any moderator we've seen :) Treatment is changing shape. Scott Shannon, MD, of The Wholeness Center put it well: the field is moving from three visit types (evaluations, therapy, and medication management) to complex, multi-hour treatments that combine dosing, therapy, and monitoring. In Denver, we saw it firsthand. More practices are offering ketamine, Spravato, and TMS together, and many are preparing for psychedelic treatments if and when they're approved. The field now has a shared definition. Our team recently published "Defining Interventional Psychiatry" in Nature Mental Health (link in comments). Operations set the ceiling on growth. Credentialing, prior authorizations, billing, charting, patient intake and retention, and REMS submissions all cost practices revenue and time. That last one is where Osmind comes in. As the partner to 1,000+ practices and 15+ life sciences companies, we give clinicians psychiatry's leading technology platform plus back-office services like revenue cycle management, so they can bring these treatments to the patients who need them most.

We’re honored to have @TIME recognize Osmind as one of the World's Top Health Tech Companies of 2026! This is the second year we made this list. What makes our mission worthwhile is the people we serve—psychiatrists and nurse practioners delivering novel treatments for depression, researchers advancing psychedelic medicine, practices scaling operations with our platform. 2026 and 2027 are breakthrough years for fast-tracking psychedelic approvals. As we sail into uncharted waters, we're working hard to ensure practices can deliver them safely and profitably when the time comes. Thank you TIME and thank you to all the mental health innovators that inspire us every day!

In 2020, our co-founders, Lucia Huang and Jimmy Qian started knocking on clinic doors because they’d seen what ketamine could do for patients who'd run out of treatment options, and how hard it was for independent practices to actually offer it. That's why they built Osmind. Today, Osmind powers the largest network of interventional psychiatry practices in the country, and we're proud to sponsor @American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3)s Mastering the Essentials again this year. Whether you're launching your first ketamine program or scaling into Spravato and TMS, we're here to help you automate admin and capture more revenue, so you focus on what matters. Good medicine can and should be good business. Find our team at our table in Denver, September 25–27. We've got an offer just for Mastering the Essentials attendees.